Delbios seeks to subcontract expert services to conduct a CMC and Non-clinical Gap Analysis, providing technical, regulatory, and scientific input to consolidate the nanoGLA development strategy.
The objective is to assess the current status of the CMC and non-clinical data packages, identify gaps or areas needing further optimization, and provide recommendations to ensure readiness for a Clinical Trial Application (CTA) submission (by October 2026) and FIH studies. Related to WP2: Tasks 2.1, 2.2 & WP3: Tasks 3.1, 3.2, 3.3.
All quotations must be submitted by [05/11/2025, 23:59 CET] to: [info@delbios.com]
Subject: RFQ-TOX-004-2025